A5089256383- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- RNA Interference and Gene Delivery
- PARP inhibition in cancer therapy
- Chronic Myeloid Leukemia Treatments
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Roswell Park Comprehensive Cancer Center
2007-2025
National Cancer Institute
2007-2024
Sidney Kimmel Comprehensive Cancer Center
2024
National Institutes of Health
2024
Center for Cancer Research
2024
Buffalo State University
2024
University at Buffalo, State University of New York
2024
Icahn School of Medicine at Mount Sinai
2023
Dana-Farber Cancer Institute
2023
University of Pittsburgh
2006-2021
Purpose We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, paclitaxel in advanced urothelial carcinoma patients prospectively evaluated human epidermal growth factor receptor-2 (Her-2/neu) overexpression rates. Patients Methods Advanced were screened for Her-2/neu overexpression. Eligibility therapy required by immunohistochemistry (IHC), gene amplification and/or elevated serum Her-2/neu, no prior...
Purpose To compare the safety and activity of DN-101, a new high-dose oral formulation calcitriol designed for cancer therapy, docetaxel with placebo docetaxel. Patients Methods progressive metastatic androgen-independent prostate adequate organ function received weekly 36 mg/m 2 intravenously 3 weeks 4-week cycle combined either 45 μg DN-101 or taken orally 1 day before The primary end point was prostate-specific antigen (PSA) response within 6 months enrollment, defined as 50% reduction...
No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy.In this phase 3, multinational, open-label trial, we randomly assigned previously untreated either receive intravenous nivolumab (at a dose of 360 mg) plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up six cycles, followed by 480 4 maximum 2 years, alone cycles. The primary outcomes were and progression-free...
Abstract Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers; however, durable response is limited to only a subset of patients. Discovery blood-based biomarkers that reflect dynamic change the tumor microenvironment, and predict ICI, will markedly improve current regimens. Here, we investigate CX3C chemokine receptor 1 (CX3CR1), marker T-cell differentiation, as predictive correlate ICI therapy. Successful tumor-bearing mice with increases frequency...
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients high-risk muscle-invasive after radical surgery unknown.
LBA531 Background: Muscle-invasive urothelial carcinoma (MIUC) is an aggressive disease with high relapse rates. Neoadjuvant platinum-based chemotherapy (NAC) the standard of care in patients (pts) who are cisplatin (Cis)-eligible. However, many pts Cis-ineligible or have persistent muscle-invasive after NAC and surgery. We evaluated pembrolizumab (Pembro) as adjuvant therapy high-risk MIUC following surgical resection. Methods: The AMBASSADOR study open-label, randomized, phase III trial...
Abstract Breast and kidney-expressed chemokine (BRAK) CXCL14 is a new CXC with unknown function receptor selectivity. The majority of head neck squamous cell carcinoma (HNSCC) some cervical do not express mRNA, as opposed to constitutive expression by normal oral epithelium. In this study, we demonstrate that the loss in HNSCC cells at primary tumor sites was correlated low or no attraction dendritic (DC) vitro, decreased infiltration mass DC site vivo. Next, found recombinant human...
Abstract Expression of androgen receptor (AR) in prostate cancer (PCa) is heterogeneous but the functional significance AR heterogeneity remains unclear. Screening ~200 castration-resistant PCa (CRPC) cores and whole-mount sections (from 89 patients) reveals 3 expression patterns: nuclear (nuc-AR), mixed nuclear/cytoplasmic (nuc/cyto-AR), low/no (AR −/lo ). Xenograft modeling demonstrates that + CRPC enzalutamide-sensitive resistant. Genome editing-derived AR-knockout LNCaP cell clones...
Lysine-specific demethylase 6A (KDM6A) and members of the Switch/Sucrose Non-Fermentable (SWI/SNF) family are known to counteract activity Enhancer Zeste Homolog 2 (EZH2), which is often overexpressed associated with poor prognosis in muscle-invasive bladder cancer. Here we provide evidence that alterations chromatin modifying enzymes, including KDM6A SWI/SNF complex, frequent We exploit loss function mutations complex make cancer cells susceptible EZH2-based epigenetic therapy activates an...
5011 Background: Patients with mCRPC inevitably develop resistance to available therapies, eg, novel hormonal agents (NHAs), and experience disease progression. Certain mutations that can in the ligand-binding domain (LBD; amino acids 671–920) of AR gene during treatment have been associated poor outcomes. ARV-766 is a novel, potent, orally administered PROTAC degrader targets wild-type clinically relevant LBD mutants, including most prevalent L702H, H875Y, T878A mutations. We report initial...
Changes either in the number or responsiveness of hematopoietic progenitors may be a major factor accounting for age-related changes stimulus driven hematopoiesis.To test these hypotheses, we compared relative proportions and CD34+ bone marrow cells from healthy young (20-30 yrs) elderly (70-80 volunteers to G-CSF, GM-CSF, IL-3 an vitro culture system.There was no difference proportion more mature subset, defined as CD34+, CD33+ cells. Maximal colony formation by stimulated with combination...
Prostate cancer cells undergo neuroendocrine differentiation during androgen deprivation and secrete neuropeptides, hence activating receptor-regulated genes. Src-family protein kinases are involved in neuropeptide-induced prostate growth migration. A phase II trial of AZD0530, an oral kinase inhibitor, patients with advanced castration resistant was conducted. The primary endpoint cancer-specific antigen (PSA) response rate, defined as a 30% or greater decrease. two-stage Simon design used....
Given the paucity of information on dose intensity, objective this study is to describe use adjuvant chemotherapy for stage III colon cancer, focusing relative intensity (RDI), overall survival (OS) and disease-free (DFS). Retrospective cohort 367 patients diagnosed with cancer in 2003–2008 treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS 3-year DFS by regimen RDI, multivariable Cox proportional hazards regression was used model these associations....
DepoVax is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cells were used as antigens create therapeutic vaccine, DPX-0907.A phase I clinical study was designed examine safety immune activating potential DPX-0907 in advanced stage patients. A total 23 late patients recruited divided into two dose/volume cohorts...
Abstract Background A high density of CD8 + tumor infiltrating lymphocytes (TILs) is associated with improved survival in multiple cancers, but its prognostic role prostate cancer remains controversial. The aim our study was to evaluate the value TILs patients undergoing radical prostatectomy (RP). We hypothesized that elevated RP specimen would correlate clinical outcomes. This information may be helpful for future immunotherapy trial design and treatment selection. Methods Tumor...
Prostate cancer (PCa) remains a common with high mortality in men due to its heterogeneity and the emergence of drug resistance. A critical factor contributing lethality is presence prostate stem cells (PCSCs), which can self-renew, long-term propagate tumors, mediate treatment MicroRNA-34a (miR-34a) has shown promise as an anti-PCSC therapeutic by targeting molecules involved cell (CSC) survival functions. Despite extensive efforts, development miR-34a therapeutics still faces challenges,...
Abstract BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved 10 to 12 cycles of docetaxel‐containing chemotherapy but further management undefined. In the current study, authors examined retreatment same regimen after a treatment holiday. Methods. Patients treated docetaxel at dose 36 mg/m 2 plus either high‐dose calcitriol (DN‐101; 45 μg) or placebo administered weekly for 3 every 4 weeks could suspend if their serum...
Abstract Purpose: The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week. Experimental Design: Escalating doses 17AAG were i.v. cohorts three six patients. Dose levels for schedule A (twice weekly × 3 weeks, every 4 weeks) 100, 125, 150, 175, 200 mg/m2 B 2 200, 250 mg/m2. Peripheral blood mononuclear cells (PBMC) collected assessment heat shock protein (HSP) 90 HSP90 client...